Theriva Biologics Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Theriva Biologics ha un patrimonio netto totale di $24.6M e un debito totale di $163.0K, che porta il suo rapporto debito/patrimonio netto a 0.7%. Le sue attività totali e le sue passività totali sono rispettivamente $40.1M e $15.5M.

Informazioni chiave

0.7%

Rapporto debito/patrimonio netto

US$163.00k

Debito

Indice di copertura degli interessi	n/a
Contanti	US$16.41m
Patrimonio netto	US$24.64m
Totale passività	US$15.47m
Totale attività	US$40.11m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $19.5M ) di SFY0 superano le sue passività a breve termine ( $7.3M ).

Passività a lungo termine: Le attività a breve termine di SFY0 ( $19.5M ) superano le sue passività a lungo termine ( $8.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SFY0 ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di SFY0 è aumentato da 0% a 0.7% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SFY0 ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: SFY0 ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 5.4 % ogni anno

Theriva Biologics Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Recent updates

Theriva Biologics, Inc. Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc. Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc., Annual General Meeting, Oct 31, 2024

High number of new and inexperienced directors

Theriva Biologics, Inc. has filed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

New major risk - Financial position

Theriva Biologics, Inc. Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation

Theriva Biologics, Inc. has filed a Follow-on Equity Offering in the amount of $1.235303 million.

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought €144k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: €1.23

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: €0.23

New 90-day low: €0.24

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: €0.37

New 90-day high - €0.59

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane